OTCMKTS:CBBT Cerebain Biotech (CBBT) Stock Price, News & Analysis $0.0009 0.00 (0.00%) As of 09/2/2021 Add Compare Share Share Stock Analysis Stock Analysis About Cerebain Biotech Stock (OTCMKTS:CBBT) Get Cerebain Biotech alerts:Sign Up Key Stats Today's Range$0.0008▼$0.001050-Day Range N/A52-Week Range$0.00▼$0.47Volume2.04 million shsAverage Volume11.21 million shsMarket CapitalizationN/AP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview Cerebain Biotech Corp. is a biotechnology company focused on developing potential treatments for Alzheimer’s disease and other neurodegenerative conditions. Its research has centered on a surgical approach involving the use of omental tissue, a fatty layer located in the abdomen, with the goal of improving blood flow and supporting brain function. The company’s work has primarily involved developing and evaluating this investigational medical procedure and related intellectual property rather than selling an established commercial pharmaceutical product. Publicly available information about clinical development, regulatory approvals, commercialization plans, and current operations is limited. Cerebain Biotech has been associated with operations in the United States. Detailed, current information about its leadership team, geographic reach, and product pipeline is not readily available from reliable public sources.AI Generated. May Contain Errors. Read More Receive CBBT Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Cerebain Biotech and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. CBBT Stock News HeadlinesCBBT expansion back in motion after crews discover centuries-old anchor, halting project for monthsAugust 29, 2024 | msn.comImClone Founder Waksal Forming New Biotech VentureOctober 28, 2023 | thestreet.comWall Street legend reveals his top AI stock before Oct. 20Marc Chaikin, the 60-year Wall Street veteran behind the Power Gauge rating system, has flagged a new AI stock ahead of October 20. His system has spotted at least seven of the top 10 performers every year since 2016, including all ten in the 2022 bear market and every member of the Magnificent Seven before their run higher. Now Chaikin's Power Gauge is turning bullish on an under-the-radar company tied to next-generation AI data centers built under Executive Order 14363, technology he says uses 99 percent less electricity and space while offering far greater computing power.October 14 at 1:00 AM | Chaikin Analytics (Ad)Duopharma Biotech Bhd (DUOP)September 19, 2023 | investing.comFormer Google AI expert raises $100mn for biotech start-upSeptember 10, 2023 | ft.comPharmAla Biotech to supply University of California Clinical Trial with LaNeo™ MDMAOctober 6, 2022 | finance.yahoo.comJapan Biotech Startups Directory 2022September 15, 2022 | finance.yahoo.comCerebain Biotech Closes Share Exchange Agreement With PKG, Inc.September 20, 2021 | finance.yahoo.comSee More Headlines CBBT Stock Analysis - Frequently Asked Questions How have CBBT shares performed this year? Cerebain Biotech's stock was trading at $0.0009 on January 1st, 2026. Since then, CBBT shares have increased by 0.0% and is now trading at $0.0009. What other stocks do shareholders of Cerebain Biotech own? Based on aggregate information from My MarketBeat watchlists, some other companies that Cerebain Biotech investors own include SNDL (SNDL), Vapor (HCMC), HUMBL (HMBL), CloudCommerce (CLWD), Galaxy Next Generation (GAXY), AMC Entertainment (AMC) and Ameritek Ventures (ATVK). Industry, Sector and Symbol Stock ExchangeOTCMKTS SectorIndustrials Industry Trading Companies & Distributors Sub-IndustryTrading Companies & Distributors Current SymbolOTCMKTS:CBBT CIKN/A Webwww.cerebain.com Phone(714) 371-4109FaxN/AEmployees2Year FoundedN/AProfitability EPS (Trailing Twelve Months)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding SharesN/AFree FloatN/AMarket CapN/A OptionableNot Optionable BetaN/A Options Trading Made Easy - Download NowLearn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.Get This Free Report This page (OTCMKTS:CBBT) was last updated on 9/2/2021 by MarketBeat.com Staff. From Our PartnersWall Street legend reveals his top AI stock before Oct. 20Marc Chaikin, the 60-year Wall Street veteran behind the Power Gauge rating system, has flagged a new AI stock...Chaikin Analytics | SponsoredHow one AI fund pays investors every ThursdayOne small fund tied to artificial intelligence stocks delivered $1,051 in a single month, not through selling ...Investors Alley | SponsoredThe Iran War Isn’t Chaos. It’s Strategy.Two thousand missiles struck Iran. Three days later, Dylan Jovine sat in two private meetings with U.S. Congre...Behind the Markets | SponsoredWhy major institutions are piling into this digital asset nowBlackRock, JPMorgan, Goldman Sachs, and Fidelity are reportedly accumulating a scarce blockchain asset - one t...Awesomely | SponsoredForget Biotech Stocks… This Is the Smarter PlayNVIDIA, Shopify, and TSMC built fortunes by powering innovation rather than betting on a single winner. One li...Compounding Quality | SponsoredThe most boring strategy I knowCovered calls won't make you rich overnight, and they cap your upside if a stock takes off. But many retired i...Profits Run | SponsoredYou waited. Micron didn't.On October 15, 2025, Seeking Alpha's Quant system added Micron Technology (MU) to its Alpha Picks portfolio. I...Seeking Alpha | SponsoredINSANE DRONE FOOTAGENew drone footage shows a mysterious factory rising at one of Elon Musk's most secure facilities, cleared and ...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cerebain Biotech Corp. Please log in to your account or sign up in order to add this asset to your watchlist. Share Cerebain Biotech With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
